In order to further verify the enrichment of ARRDC2 in the immune-related signaling pathways of ovarian cancer, GSEA was used to analyze the data of two groups of OV patients from the TCGA database (ARRDC2 high expression group and ARRDC2 low expression group). This evidence concerns the gene ARRDC2 and ovarian carcinoma.